Fractyl Health, which focuses on developing new treatments for obesity and type 2 diabetes, reported the latest data on its preclinical GLP-1 gene therapy Rejuva at the 84th American Diabetes Association (ADA) scientific conference.
Fractyl Health (GUTS.US), which focuses on developing new treatments for obesity and type 2 diabetes, reported the latest data on its preclinical GLP-1 gene therapy Rejuva at the 84th American Diabetes Association (ADA) scientific conference. In a mouse model of obesity, a single dose of Rejuva treatment reduced fat mass and improved blood sugar levels. Rejuva also prevented weight and blood sugar rebound after the cessation of semaglutide. In addition, the study data first demonstrated the potential of Rejuva treatment to simulate the natural release of GLP-1 from the pancreas.
Rejuva is a GLP-1 pancreatic gene therapy project (PGTx) based on an adenovirus (AAV) developed by Fractyl Health, aimed at achieving sustained production of GLP-1 in the pancreas for the treatment of obesity and type 2 diabetes.
The latest study compared the effects of a single dose of Rejuva and daily semaglutide treatment on body composition and blood sugar parameters in a diet-induced obesity (DIO) mouse model. The study also investigated the effects of a single dose of Rejuva on DIO mice after the cessation of semaglutide.